Study S001548

An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01785771
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: TERMINATED
Enrollment: 100
Start: 2013-05
Primary completion: 2018-01
Lead sponsor: Intarcia Therapeutics
Conditions: Type 2 Diabetes
Interventions: DRUG:ITCA 650 (exenatide in DUROS)
Results posted: FALSE

Registered primary outcomes

Change in HbA1c between Week 39 and Day 0 [39 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011254	Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Henry RR, Diabetes care	2018	Randomized trial	PMID 29301824 DOI	cites ClinicalTrials.gov:NCT01785771; registry reference DERIVED:29301824